Medical Care Technologies Inc. (OTC Pink:MDCE) Sees Significant Surge in Investor Activity as Share Structure Stabilizes and New Tech Partnership Forms

Rhea-AI Summary

Medical Care Technologies (OTC Pink: MDCE) announced increased trading activity and shareholder engagement as of December 9, 2025, citing a stabilization of its share structure after the close of dilution tied to a prior Regulation A offering.

The company highlighted accelerating development of AI health tools, including a Google-backed AI dermatology and wound-monitoring platform for melanoma detection and chronic wound management, plus expanded technical advisory and integration efforts as catalysts for renewed investor interest.

Management said these advances support a path toward consumer testing, commercialization, and long-term revenue execution, and that further updates will follow as execution milestones are reached.

Positive

• Reg A dilution concluded, improving share-structure stability
• Google-backed AI dermatology and wound-monitoring platform announced
• Rising trading volume and share price indicating renewed investor interest
• Accelerated product development timelines toward consumer testing

Negative

• None.

MESA, ARIZONA / ACCESS Newswire / December 9, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is pleased to announce a marked rise in trading activity and shareholder engagement as the Company transitions into a new phase of technology-driven growth and leaves behind dilution tied to its previous Regulation A offering.

Over recent trading sessions, MDCE has experienced substantial increases in both share price and trading volume, signaling renewed attention from retail and strategic investors tracking the Company's emerging footprint in the high-growth AI health-technology sector.

This shift aligns with the Company's accelerated development of artificial intelligence tools-particularly its Google-backed AI dermatology and wound-monitoring platform, designed to support early detection of melanoma and the remote management of chronic wounds for millions of patients globally.

"This renewed momentum reflects a clear vote of confidence in our direction and in the future we're building," stated CEO Marshall Perkins III.
"With dilution from our prior Reg A ending and new AI partnerships propelling us forward, MDCE is entering an exciting era of innovation and value creation."

Growth Drivers Supporting Investor Excitement

MDCE attributes this increasing market interest to several key catalysts:

• Conclusion of Reg A dilution - creating a more stable and attractive share structure
• New AI-health technology integrations - including melanoma-detection capabilities
• Accelerated product development timelines
• Expansion of technical advisory and integration collaboration efforts
• Growing visibility across the investor community

Together, these advancements establish a strong foundation as MDCE scales toward consumer testing, commercialization, and long-term revenue execution.

Positioned to Capture Major Market Opportunities

With dermatology and wound-care markets representing a combined multi-billion-dollar global opportunity, MDCE believes its mobile, consumer-focused AI strategy is ideally positioned to disrupt conventional preventive-care models.

"We are moving fast, building smart, and driving toward a future where AI health tools are widely accessible," added Perkins.
"Our shareholders are recognizing the scale of what we're creating, and this is only the beginning."

MDCE will continue to provide updates as execution milestones are reached.

About Medical Care Technologies Inc. (OTC Pink:MDCE)

Medical Care Technologies Inc. is an emerging leader in AI-driven preventive and remote health solutions. The Company develops intelligent imaging tools that enable users and care providers to identify and manage critical health conditions earlier and more effectively-from any smartphone, anywhere in the world.
Learn more at: www.medicalcaretechnologies.com

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding anticipated market performance, technology development, milestones, financial expectations, regulatory strategy, and shareholder value creation. Forward-looking statements involve risks and uncertainties. Actual results may differ materially. MDCE undertakes no obligation to update or revise forward-looking statements to reflect future developments or events.

Contact:

Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com

SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)

View the original press release on ACCESS Newswire

FAQ

What did Medical Care Technologies (MDCE) announce on December 9, 2025 about share structure?

The company said dilution from its prior Regulation A offering has ended, creating a more stable share structure.

What AI product developments did MDCE describe in the December 9, 2025 announcement?

MDCE described a Google-backed AI dermatology and wound-monitoring platform for melanoma detection and remote chronic-wound management.

How is investor interest changing for MDCE according to the December 9, 2025 release?

The company reported substantial increases in trading volume and share price, signaling renewed retail and strategic investor attention.

What next steps did MDCE outline for commercialization after the December 9, 2025 update?

MDCE said it is scaling toward consumer testing and commercialization and will provide updates as execution milestones are reached.

Does the MDCE announcement on December 9, 2025 mention revenue or earnings figures?

No; the announcement highlights development progress and market activity but does not disclose revenue or earnings figures.